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Acute massive pulmonary embolism (PE) is a common life-threatening condition requiring 
emergent and suitable treatment.  The aim of this study is to assess the efficacy and safety 
of local thrombolysis with a pulse-infusion-thrombolysis (PIT) catheter in the management 
of acute massive PE.  Thirty-nine patients with PE were treated with catheter directed 
intervention (CDI).  CDI involves suction embolectomy and local thrombolysis with a PIT 
catheter.  Procedural success was achieved in all patients (100%).  After the CDI, a signifi-
cant increase of mean systemic blood pressure was observed (93.8 ± 22.0 mmHg versus 
100.8 ± 22.9 mmHg, P = 0.02), and pulmonary perfusion on the basis of Miller score was 
improved (19.6 ± 7.6 versus 16.3 ± 7.1, P = 0.04).  Clinical success was achieved in 36 of 39 
patients (92.3%).  Two patients died of PE after CDI despite a successful recanalization, 
and 1 patient died of disseminated intravascular coagulation after the CDI.  No major 
complication occurred in the remaining 36 patients and minor complications developed in 
3 patients (7.7%).  Local thrombolysis using a PIT catheter for massive PE is safe and ef-
fective treatment with minimal complication.
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Acute massive pulmonary embolism (PE) is de-
fined as a life-threatening condition with high mor-
tality (Goldhaber et al., 1999; Kucher et al., 2006; 
Tapson, 2008).  Especially, patients with massive 
PE are at serious risk of death due to right ven-
tricular failure and the presence of hemodynamic 
instability within the first hour of onset (Adam et 
al., 2008).  Survival depends on rapid recanaliza-
tion of the pulmonary arterial occlusion and reduc-
tion of the right ventricular afterload.  The standard 
medical management for patients with massive PE 
is systemic thrombolysis using a tissue plasmino-
gen activator (t-PA) or a novel modified t-PA, mon-
teplase (Buller et al., 2004).  This treatment is as-
sociated with hemorrhagic risks, and some patients 
cannot receive systemic thrombolysis due to con-
traindications.  Catheter directed intervention (CDI) 
is an alternative therapy for patients with massive 
PE with contraindications to systemic thromboly-
sis, and this method is considered to be much less 
invasive than the open surgery.  CDI includes sev-
eral interventional techniques, for example, suction 
embolectomy and local thrombolysis (Blaustein 
et al., 2004; Kuo et al., 2009).  CDI with local ad-
ministration of a thrombolytic agent, urokinase 
and t-PA has been used by several investigators 
(Verstraete et al., 1988; Gonzales-Juanatey et al., 
1992; Kucher, 2007).  A recent study (Yamamoto 
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et al, 2009) showed that CDI with monteplase was 
effective for major PE; however, the safety and ef-
ficacy of local thrombolysis by CDI still remains 
controversial.  Pulse infusion thrombolysis (PIT) 
is available for thrombotic diseases such as deep 
venous thrombosis, because of forceful delivery of 
thrombolytic agent in a spray-like fashion through 
multiple side holes (Hokimoto et al., 2008).  This 
technique was first applied to peripheral artery 
and shunt thrombotic occlusion by Bookstein et al. 
(1989).  In the present study, we used a PIT catheter 
(Senko Medical Instrument, Tokyo, Japan) for local 
thrombolysis of PE, and evaluated the safety and 
efficacy of CDI, and also demonstrated the early 
and late outcomes.
 
 
Materials and Methods
 
Subjects
 
Between January 2006 and August 2009, 113 con-
secutive patients referred to our department for sus-
pected of acute PE, of whom 43 patients met cri-
teria for acute massive PE confirmed by contrast-
enhanced computerized tomography and one or 
Table 1.  Patients’ baseline characteristics
 Patient
 n    (%)
Male/female ratio 15/24
Age (year) 67.9 ± 13.7
Prior deep venous thrombosis 26 (66.7)
Cancer   3 (  7.7)
Time after major surgery (< 15 days)   4 (10.3)
Smoking   7 (17.9)
Obesity 11 (28.1)
High risk pulmonary embolism  12 (30.8)
Cardiopulmonary arrest   2 (  5.1)
Right ventricular dysfunction 26 (66.7)
Inferior vena cava filter 27 (69.2)
Treatment time (min) 89.2 ± 24.6
Data are number (n) and percentage of patients; except age 
and treatment time shown in mean ± SD, and male/female 
ratio.  
Total number of patients, 39.
more criteria right ventricular dysfunction (RVD) 
without hypotension.  We enrolled 39 patients for 
CDI using the PIT catheter, except 4 patients who 
had contraindication for thrombolysis.
 The clinical definition of massive PE was es-
tablished in the presence of cardiogenic shock or 
hypotension, the latter defined as systemic systolic 
blood pressure (SBP) < 90 mmHg, or a pressure 
drop > 40 mmHg for > 15 min not caused by ar-
rhythmia, hypovolemia or sepsis (Adam et al., 
2008).  In all patients, RVD was confirmed by tr-
ansthoracic echocardiography before angiography. 
The criteria applied for the diagnosis of RVD were 
a diastolic diameter of the right ventricle > 30 mm, 
a right ventricular diastolic diameter/left ventricu-
lar diastolic diameter ratio > 1, paradoxical septal 
movement, hypokinesia of the right ventricular 
free wall, loss of inspiratory collapse of the inferior 
vena cava, and tricuspid regurgitation at a velocity 
> 2.5 m/s in the absence of inspiratory collapse of 
the inferior vena cava or > 2.8 m/s (Wood, 2002).
 Written informed consent for CDI and the 
potential use of the PIT was obtained in the early 
phase of admission.  The study protocol was in 
agreement with the guidelines of Human Ethics 
Committee of the institution.  If a patient was un-
conscious and receiving respiratory therapy at the 
time of inclusion in the study, the ethics committee 
was notified of the inclusion, and consent was ini-
tially obtained from the family.
 Baseline characteristics of patients are de-
scribed in Table 1.  There were 15 men and 24 
women with mean age of 67.9 ± 13.7 years.  The 
most frequent risk factor was deep vein thrombosis 
(67%).  Twelve were high-risk patients for PE with-
systemic SBP < 90 mmHg or shock index > 0.9. 
Two patients were in the state of cardiopulmonary 
arrest.  RVD was observed in 26 patients (66.7%) 
by transthoracic echocardiology before procedure. 
Three patients became cardiopulmonary arrest and 
underwent cardiopulmonary resuscitation.  Before 
local thrombolytics, 27 patients (69.2%) with deep 
venous thrombosis were implanted inferior vena 
cava filter to inhibit the recurrence of PE.
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Hand PIT system
 
The hand PIT system consists of a hand PIT pump 
and a PIT catheter (Fig. 1).  The hand PIT pump al-
lows intermittent spray-like drug delivery through 
Fig. 1.  Hand pulse-infusion-thrombolysis (PIT) system.  The powered pump is attached to a 2.5-mL syringe.  The T-
shaped, one-way valve allows forceful propulsion of the thrombolytic drug and also aspiration of emboli through the PIT 
catheter.
Fig. 2.  Pulse-infusion-thrombolysis catheter.  This cath-
eter has spirally placed side-holes that make it possible to 
inject thrombolytic agent in a spray-like fashion. 
a PIT catheter (Fig. 2).  The side holes of the PIT 
catheter are placed into the thrombus and the hand 
PIT pump allows forcefully directed delivery of 
thrombolytic agent into the thrombus.  This system 
makes it possible to increase the drug contact sur-
face and to accelerate the thrombolytic process. 
 
Procedure
 
In this study, CDI involves suction embolectomy 
and local thrombolysis with the hand PIT system. 
We used monteplase or urokinase as a thrombolytic 
agent on the basis of the severity of patient condi-
tion.  Monteplase was used when the hemodynamic 
improvement of the patient was needed as soon as 
possible because of instable condition, otherwise 
urokinase was used (Sors et al., 1994).  CDI was 
performed by a 6- to 8-Gauge French short sheath 
introduced into the femoral vein or internal jugular 
vein.  When the transfemoral access was consid-
AB
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Fig. 3.  Pulmonary angiograms in a 65-year-old woman 
with massive pulmonary embolism.
A: Pretreatment image shows emboli in the left lower 
lobe artery (arrowhead).  The pulmonary artery 
pressure (PAP) was 33/19 mmHg (mean, 25 mmHg), 
and the Miller score was 14.
B: Local thrombolysis was performed using the pulse 
infusion thrombolysis catheter.
C: Posttreatment image shows complete recanalization 
of pulmonary artery occlusion.  The PAP was 30/10 
mmHg (mean, 18 mmHg), and the Miller score was 
10.
ered to be contraindicated in case of iliocaval or 
ipsilateral femoral venous thrombus, we selected 
the transjugular route.  If deep venous thrombosis 
was confirmed by venous ultrasound or contrast-
enhanced computerized tomographic images, an 
inferior vena cava filter was inserted through the 
delivering catheter and implanted below the level 
of the renal vein.
 Immediately after the diagnosis of PE, intra-
venous unfractionated heparin was started with 
a bolus dose of 5,000 IU, followed by continuous 
infusion with 10,000 to 15,000 IU/day.  Pulmonary 
artery pressure (PAP) was measured by Swan-
Ganz-catheter (Baxter Healthcare, Irvine, CA) in 
the pulmonary artery trunk just before and imme-
diately after CDI.  After hemodynamic measure-
ment had been taken, pulmonary angiography was 
performed in all patients using a combination of 
digital subtraction angiography and conventional 
film angiography through a 6- to 8-Gauge French 
Judkins right guide-catheter (Terumo, Tokyo, 
Japan) using iopromide 240 mgI/mL as a contrast 
medium.  Angiography was performed with the 
catheter placed in the pulmonary trunk and selec-
tively in the right and left main pulmonary arter-
ies.  We assessed the extent of thrombus formation 
by a scoring system of Miller et al. (1971).  In this 
method, the right and left main pulmonary arter-
ies are considered to have nine and seven major 
branches, respectively, and an embolus in any of 
these branches is scored as 1 point.  The maximum 
possible score for involvement is 16 points.  In ad-
dition, the effect of embolism on pulmonary artery 
flow is scored as follows: each lung is considered to 
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have an upper, middle and lower zones, and in each 
of these 3 zones, the absence of pulmonary artery 
flow is scored as 3 points; severely reduced flow, 
2 points; mildly reduced flow, 1 point; and normal 
flow; 0 point.  The maximum score for reduction 
in pulmonary artery flow is therefore 9 points for 
each lung (total 18), and the maximum possible 
score for flow reduction and involvement of arteries 
by embolism is 34 points.  Thus the Miller score 
ranges from 0 to 34 with higher scores reflecting 
greater pulmonary involvement.
 After pulmonary angiography, suction em-
bolecomy was performed for each pulmonary 
artery with the guide-catheter described above. 
Monteplase or urokinase was administered by the 
PIT system (Fig. 3).  Dose of thrombolytic agent 
was adjusted at minimum according to the angio-
graphic findings, hemodynamic status, and bleed-
ing risk.  The effectiveness of CDI was assessed by 
hemodynamic improvement and the Miller score. 
Finally, pulmonary angiography was performed for 
measurement of the postprocedure Miller score, 
and PAP was measured again.
 After the CDI, all patients were usually sent 
to coronary care unit and monitored for the evalu-
ation of complications.  After stabilization of the 
patient’s general condition, oral warfarin was also 
started and was continued for ≥ 6 months, with 
the adjustment to maintain the international nor-
malized ratio between 2 and 3.  Major procedural 
complications by CDI were defined as follows: 
hemorrhage requiring blood transfusion, cardiac 
tamponade, pulmonary artery perforation, cerebral 
vascular accident, and/or death.  Minor procedural 
complications were defined as follows: catheter-
related infection and hematoma at the puncture site 
or hemoptysis not requiring transfusion (Kucher, 
2007).
  
Assessment of efficacy
 
The procedural success was evaluated by the 
Miller score after the therapy.  The hemodynamic 
status of the patient was evaluated by the shock in-
dex obtained from dividing heart rate by systemic 
SBP which is an indicator of acute critical illness 
(Rady et al., 1994).  Other variables analyzed to 
evaluate the effect of the therapy were mean PAP, 
mean SBP and RVD on transthoracic echocardiog-
raphy before and after treatment.  Clinical success 
was defined as the stabilization of hemodynamic 
parameter, the resolution of shock, the complete 
weaning off ventilatory and inotropic support and 
survival until discharge from the hospital.  Mid-
term outcomes were defined as most recent pa-
tient’s condition after discharge including analysis 
of occurrence of cardiovascular death, recurrent PE 
and RVD on transthoracic echocardiography (Liu 
et al., 2003).
 
Statistical analysis
 
The data were analyzed using the Student t-test for 
the comparison of paired samples.  A P value < 0.05 
was considered to be statistically significant. 
 
Results
 
Procedure success rate
 
Procedural success was achieved in all patients 
(100%).  As a thrombolytic agent, urokinase was 
used in 12 patients at mean dose of 340,000 ± 
177,866 U, and monteplase in 27 patients with 
12,836 ± 5619 IU/kg.  Mean total procedure time 
was 89.2 ± 21.0 min. 
 Hemodynamic and angiographic parameters 
before and after the procedure are shown in Table 2. 
After CDI, a significant increase of mean SBP was 
observed (93.8 ± 22.0 mmHg versus 100.8 ± 22.9 
mmHg, P = 0.02), and a significant decrease of the 
Miller score was observed (19.6 ± 7.6 versus 16.3 
± 7.1, P = 0.04).  On the other hand, systolic SBP, 
mean PAP and shock index were not significantly 
different.
 
In-hospital outcome
 
Clinical success was achieved in 36 of 39 patients 
(92.3%).  Two patients died of PE after CDI despite 
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a successful recanalization, and 1 patient died of 
disseminated intravascular coagulation 5 days after 
the treatment.  Overall mortality was 7.7% (3/39 
patients).  No major complication such as perfora-
tion of pulmonary artery occurred in the remaining 
36 patients.  Minor complications developed in 3 
of 39 patients (7.7%) (hematoma at the puncture 
site, 1 patient; hemoptysis, 2 patients).  Thirty-six 
patients survived and remained stable until the 
discharge (mean duration 18.1 ± 7.7 days).  RVD 
was observed in 6 patients (15.4%) at the point of 
discharge, while observed in 24 patients (61.5%) at 
admission.
Mid-term outcome
 
Follow-up information after discharge was ob-
tained from 33 patients (mean follow-up 25.3 ± 
16.9 months).  One patient died during follow-
up period because of gynecological cancer (1/33 
patients, 3.0%).  Other patients were confirmed to 
be alive.  Recurrent PE was not observed during 
follow-up period.  RVD was observed in 4 patients 
(11.1%) after discharge.
 
Discussion
No randomized clinical trials have been under-
taken to evaluate the efficacy and safety of local 
thrombolysis with the PIT system for massive PE. 
Acute massive PE is defined as a life-threatening 
condition with high mortality (Goldhaber et al., 
1999).  Patients with massive PE are at serious risk 
of death due to RVD within the first hours of onset 
(Dalen and Alpert, 1975).  Survival depends on 
rapid recanalization of the pulmonary arterial oc-
clusion and reduction of the right ventricular after-
load.  The American College of Chest Physicians 
and the European Society of Cardiology have rec-
ommended thrombolytic therapy for these patients 
(Buller et al., 2004). 
 There are 2 approaches to administrate 
thrombolytic agent: systemic and local thromboly-
sis with CDI, which is controversial.  The standard 
treatment for massive PE is systemic thrombolysis 
(Buller et al., 2004); however, some patients cannot 
receive systemic thrombolysis due to contraindi-
cations.  Although some authors reported no dif-
ference for prognosis between these approaches, 
several reports showed that local thrombolysis 
improves severe hemodynamic impairment rapidly 
and safety in patients with acute PE (Tajima et al., 
2004; Kuo et al., 2009; Yamamoto et al., 2009).  In 
our series, local thrombolysis was adopted.  In our 
study, 36 patients with acute PE were treated by 
CDI with a clinical success rate of 92.3% that is 
higher than previous review (Kuo et al., 2009).  In-
hospital mortality (7.7%) is lower than that reported 
by International Cooperative Pulmonary Embolism 
Registry investigation (11.4%, 2 weeks) (Goldhaber 
et al., 1999). 
 PIT has previously been described as an ef-
fective device for treating deep venous thrombo-
sis or acute myocardial infarction (Hokimoto et 
al., 2008; Kuo et al., 2009).  PIT catheter makes 
it possible to lyse thrombus using the synergetic 
mechanisms of mechanical maceration by direct 
Table 2.  Hemodynamic and angiographic parameters
 Before procedure After procedure P value
Systemic SBP (mmHg) 131.8 ± 30.1 138.9 ± 31.7 0.31
Mean SBP  (mmHg)   93.8 ± 22.0 100.8 ± 22.9 0.02
Mean PAP  (mmHg)   33.4 ± 10.4   33.1 ± 9.7 0.19
Miller score    19.6 ± 7.6   16.3 ± 7.1 0.04
Shock index      0.71 ± 0.28     0.64 ± 0.29 0.34
Shown are mean ± SD.
PAP, pulmonary artery pressure; SBP, systolic blood pressure. 
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spray-like delivery of thrombolytic agent into the 
thrombus.  Hence, a high concentration of drug is 
delivered into the thrombus, resulting in lower dose 
of the drug.  In the present study, the use of a mean 
dose of thrombolytic agent was approximately half 
of the recommended dose.  We consider that it con-
tributes to reduce the risk of hemorrhage complica-
tion in our study.  
 Regression of right ventricular overload has 
been shown in previous studies after CDI, and rap-
id recovery from RVD is associated with reduced 
morbidity and mortality (Adam et al., 2008).  In 
our study, PAP indicating right ventriclular over-
load was not significantly different before and im-
mediately after CDI.  However, RVD confirmed by 
transthoracic echocardiography was significantly 
reduced at the discharge. 
 Reported complications associated with CDI 
include right ventricular perforation, significant 
bleeding at the puncture site (2%), mechanical 
hemolysis, and blood loss (Kucher, 2007; Skaf et 
al., 2007; Eid-Lidt et al., 2008).  There were no ma-
jor complications related to the catheter procedure 
in our study.  Although disseminated intravascular 
coagulation occurred at 5 days after CDI in 1 pa-
tient, association with CDI is unclear.  As minor 
complications, hematoma was documented in 1 
patient.  No recurrence of PE or cardiovascular 
death was documented in our study during follow-
up.  The absence of PE recurrence could probably 
be related to the use of inferior vena cava filter and 
oral warfarin administration in patients confirmed 
as with DVT (Adam et al., 2008).
 The present study possesses some limitations 
regarding non-randomized study, small samples 
from a single institution and retrospective design, 
which may have introduced variability in the uni-
formity of data collection.  Although prospective 
studies are needed to confirm the effectiveness of 
this local thrombolysis with the PIT system, we 
believe that this treatment should be effective for 
patients with massive PE accompanied by unstable 
hemodynamics when there is insufficient time to 
infuse intravenous thrombolytics.
 In conclusion, local thrombolysis using a PIT 
catheter for massive PE is safe and effective treat-
ment with minimal complication. 
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